Evidence map›Paper›PMID 37308792›Full record

ArticleWiener klinische Wochenschrift2023

Clinical significance of adjuvant therapy after radical surgery for primary osteosarcoma of the jaws.

Shenghong Wu, Yu Wang, Jinfeng Zhang, Zhonghui He, Yuanjue Sun, Ming Ye

Abstract read
PubMed Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Shenghong WuDepartment of Medical Oncology, Fengxian District Central Hospital, 201499, Shanghai, China.
Yu WangDepartment of Oncology, Huashan Hospital, Fudan University, 200040, Shanghai, China.
Jinfeng ZhangDepartment of Medical Oncology, Fengxian District Central Hospital, 201499, Shanghai, China.
Zhonghui HeDepartment of Medical Oncology, Fengxian District Central Hospital, 201499, Shanghai, China.
Yuanjue SunDepartment of Medical Oncology, Sixth People's Hospital, Shanghai Jiao Tong University, 201306, Shanghai, China.
Ming YeDepartment of Radiotherapy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, No.160 Pujian Road, 200127, Shanghai, China. yemingrenji@163.com.
Xian Central Hospital · CNFudan University · CNRenji Hospital · CNShanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteosarcoma of the jaw is one of the rare malignancies and the role of postoperative adjuvant therapy is unclear. This study explored the efficacy of adjuvant therapy after radical surgery for primary osteosarcoma of the jaw.

methodsThe data were retrospectively analyzed from May 2012 to June 2021. The recurrence rate, disease-free survival (DFS) and 5‑year overall survival (OS) rate were calculated by Kaplan-Meier method. Intergroup rates were examined by chi-square test.

results125 post-radical surgery patients were included. The median follow-up time was 66 months. Forty five cases suffered recurrence. The recurrence rate was 36.0%, and the 5‑year OS rate was 68.8%. In the adjuvant treatment group, twenty eight of 99 patients experienced disease progression. In the surgical treatment alone group, seventeen of 26 patients experienced disease progression. The recurrence rates in the two groups were 28.3 and 65.4%, respectively (χ

conclusionAdjuvant therapy is one of the effective measures to reduce the relapse rate and improve OS after radical surgery for primary osteosarcoma of the jaw.

Indexed as

Clinical RelevanceOsteosarcomaDisease ProgressionHumansJawNeoplasm Recurrence, LocalRetrospective StudiesAdjuvant therapyDistant metastasisLocal recurrenceOsteosarcoma of the jawSurvival

Identifiers

PMID37308792
OpenAlexW4380359044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.